pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·5h ago·1 min read
save

Trump expected to nominate Heidi Overton as new FDA commissioner

Aug 19, 2026·read at Endpoints ↗RegulatoryNeutral

President Donald Trump is expected to nominate Heidi Overton as the next commissioner of the U.S. Food and Drug Administration, according to a source familiar with the decision.

Overton's selection would mark a new chapter for the agency following a period of volatile leadership, though the article provides no further details about her background or the nomination process.

The announcement was reported in an August 18, 2026 article, and the source indicated that the nomination is pending formal confirmation.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Trump to pick Heidi Overton to lead the FDA”

read at Endpoints ↗
102 words · retrieved 4h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Sionna Therapeutics, Inc.2

related stories

  • Jun 3Mineralys makes money moves before looming hypertension approvalEndpoints
  • Jun 2#ASCO26: Celcuity plans another FDA filing after positive breast cancer readoutEndpoints
  • Jun 2Praxis sinks on late-stage study fail for seizure pill, halts second trialEndpoints
  • May 29#ASCO26: Bristol Myers details Phase 3 trial win for Pomalyst successorEndpoints
  • May 16Makary resigns; Biogen reports Alzheimer’s data; and moreEndpoints